124 related articles for article (PubMed ID: 11910829)
1. [Bacterial airway infections. Standard antibiotics more often ineffective].
MMW Fortschr Med; 2002 Feb; 144(8):52. PubMed ID: 11910829
[No Abstract] [Full Text] [Related]
2. [A new antibiotic against respiratory tract infections. More power against pneumococci].
MMW Fortschr Med; 2001 Nov; 143(44):59. PubMed ID: 11732406
[No Abstract] [Full Text] [Related]
3. Clinical efficacy of ketolides in the treatment of respiratory tract infections.
Reinert RR
J Antimicrob Chemother; 2004 Jun; 53(6):918-27. PubMed ID: 15117934
[TBL] [Abstract][Full Text] [Related]
4. [Resistance of respiratory tract infection agents is still increasing. Is its time for new antibiotic strategies?].
MMW Fortschr Med; 2003 Feb; 145(9):55. PubMed ID: 12666535
[No Abstract] [Full Text] [Related]
5. [Telithromycin: a new therapeutic option for community-acquired respiratory infection].
Muñoz MJ; Azanza JR; Escolar M; Macaya A; Gil FJ
Rev Med Univ Navarra; 2002; 46(3):37-44. PubMed ID: 12685116
[No Abstract] [Full Text] [Related]
6. Telithromycin (Ketek) for respiratory infections.
Med Lett Drugs Ther; 2004 Aug; 46(1189):66-8. PubMed ID: 15314586
[No Abstract] [Full Text] [Related]
7. Evolving resistance patterns in community-acquired respiratory tract pathogens: first results from the PROTEKT global surveillance study. Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin.
Felmingham D
J Infect; 2002 Feb; 44 Suppl A():3-10. PubMed ID: 12150493
[TBL] [Abstract][Full Text] [Related]
8. [Evaluation of ketoride antibiotics, telithromycin in treatment of respiratory tract infections (discussion)].
Kohno S; Watanabe A; Aoki N; Niki Y
Jpn J Antibiot; 2003 Dec; 56(6):531-45. PubMed ID: 15007871
[No Abstract] [Full Text] [Related]
9. Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens.
Agouridas C; Denis A; Auger JM; Benedetti Y; Bonnefoy A; Bretin F; Chantot JF; Dussarat A; Fromentin C; D'Ambrières SG; Lachaud S; Laurin P; Le Martret O; Loyau V; Tessot N
J Med Chem; 1998 Oct; 41(21):4080-100. PubMed ID: 9767644
[TBL] [Abstract][Full Text] [Related]
10. From macrolides to ketolides: What is available for the treatment of outpatient respiratory tract infections?
Carter PL
Postgrad Med; 2002 Sep; 112(3 Suppl):18-25. PubMed ID: 19667591
[TBL] [Abstract][Full Text] [Related]
11. Will resistance to ketolides develop in Streptococcus pneumoniae?
Leclercq R
J Infect; 2002 Feb; 44 Suppl A():11-6. PubMed ID: 12150490
[TBL] [Abstract][Full Text] [Related]
12. Community-acquired respiratory tract infections caused by resistant pneumococci: clinical and bacteriological efficacy of the ketolide telithromycin.
Fogarty CM; Kohno S; Buchanan P; Aubier M; Baz M
J Antimicrob Chemother; 2003 Apr; 51(4):947-55. PubMed ID: 12654763
[TBL] [Abstract][Full Text] [Related]
13. [Telithromycin in the management of lower respiratory tract infections in the hospital].
Léophonte P
Presse Med; 2003 Jun; 32(20):952-3. PubMed ID: 12876542
[No Abstract] [Full Text] [Related]
14. [Importance in respiratory tract infections. Ketolides: clinical aspects].
Lorenz J; Steiert P
Pharm Unserer Zeit; 2004; 33(1):42-6. PubMed ID: 14968712
[No Abstract] [Full Text] [Related]
15. [Multicenter study in southern South America of the in vitro activity of telithromycin in strains with defined resistance phenotypes isolated from community-acquired respiratory infections].
Casellas JM; Visser M; Mac Dougall N; Coco B; Tomé G; Gliosca L;
Rev Esp Quimioter; 2001 Sep; 14(3):269-74. PubMed ID: 11753448
[TBL] [Abstract][Full Text] [Related]
16. In vivo efficacy of telithromycin (HMR3647) against Streptococcus pneumoniae and Haemophilus influenzae.
Okamoto H; Miyazaki S; Tateda K; Ishii Y; Yamaguchi K
Antimicrob Agents Chemother; 2001 Nov; 45(11):3250-2. PubMed ID: 11600393
[TBL] [Abstract][Full Text] [Related]
17. Newer oral antimicrobials for resistant respiratory tract pathogens. Which show the most promise?
Stein GE; Havlichek DH
Postgrad Med; 1998 Jun; 103(6):67-70, 74-6. PubMed ID: 9633543
[TBL] [Abstract][Full Text] [Related]
18. The evolution of antimicrobial agents used for the management of CARTIs: a focus on a new class of antimicrobials--the ketolides.
Sbarbaro JA
Am J Manag Care; 2004 Oct; 10(12 Suppl):S389-99. PubMed ID: 15603248
[No Abstract] [Full Text] [Related]
19. Comparative activity of telithromycin against typical community-acquired respiratory pathogens.
Buxbaum A; Forsthuber S; Graninger W; Georgopoulos A
J Antimicrob Chemother; 2003 Sep; 52(3):371-4. PubMed ID: 12888585
[TBL] [Abstract][Full Text] [Related]
20. [Variations of microbial sensitivity in lower respiratory tract infections].
Aguerre MM; Costa de Mello B
Hoja Tisiol; 1971; 28(1-2):41-76. PubMed ID: 5173683
[No Abstract] [Full Text] [Related]
[Next] [New Search]
